ArticleTranslational cancer research2021
High expression of Dll4 and CD44V6 is associated with clinicopathological characteristics and poor prognosis in osteosarcoma patients.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody.Journal of gastrointestinal cancer · 2024Article
- Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.Signal transduction and targeted therapy · 2024Review
- Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis.Cancer science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma is a malignant tumor with a poor prognosis. Dll4 and CD44V6 are involved in the regulation of tumor development. This study aims to analyze the expression of Dll4 and CD44V6 in osteosarcoma and the correlation with clinicopathological characteristics and prognosis.
methodsClinical data of 47 patients with osteosarcoma admitted to our hospital from April 2016 to May 2018 and confirmed by surgery or pathological examination were retrospectively analyzed. Osteochondroma and normal bone tissues from these cases were taken as controls. The protein levels of Dll4 and CD44V were detected by immunohistochemistry (IHC). The relationship between the expression of Dll4 and CD44V and the clinicopathological characteristics of patients with osteosarcoma was analyzed. An unconditional multi-factor logistic regression model was used to analyze the risk factors affecting the prognosis of patients with osteosarcoma.
resultsThe positive expression rates of Dll4 and CD44V6 in osteosarcoma were 85.11% (Dll4) and 91.49% (CD44V6), which were significantly higher than those in normal bone tissues of 18.52% (Dll4) and 7.41% (CD44V6), and in osteochondroma of 22.22% (Dll4) and 7.41% (CD44V6). The expression of CD44V6 and Dll4 were related to the Enneking stage and metastasis (P<0.05), and the expression of Dll4 was closely related to the degree of tumor differentiation (P<0.05). The 2-year survival rates of patients with Dll4 or CD44V6 positive expression were 25.00% and 21.88%, respectively, which were significantly lower than those with Dll4 or CD44V6 negative expression (85.71% and 93.33%) (P<0.05). The results of the unconditional multivariate logistic regression analysis showed that low tumor differentiation, high Enneking stage, metastasis, and positive expression of Dll4 and CD44V6 were risk factors affecting the mortality rate and prognosis of patients with osteosarcoma (P<0.05).
conclusionsThe positive expression rate of Dll4 and CD44V6 in osteosarcoma is high, and the expression level is closely related to the degree of tumor differentiation, Enneking stage, and metastasis. Dll4 and CD44V6 are risk factors affecting the survival prognosis for patients. Therefore, in clinical settings, the prognosis for patients could be evaluated by detecting the expression of Dll4 and CD44V6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.